Jia R B, Zhang P, Zhou Y X, Song X, Liu H Y, Wang L Z, Luo M, Lu J, Ge S F, Fan X Q
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Ophthalmic Res. 2007;39(2):108-15. doi: 10.1159/000099247. Epub 2007 Feb 2.
Vascular endothelial growth factor (VEGF) is one of the most important angiogenic growth factors for tumor angiogenesis which has been verified to be involved in neovascularization of retinoblastoma. Here, we sought to explore whether RNA interference (RNAi) targeting VEGF could inhibit retinoblastoma angiogenesis and tumor growth. Stable transfection of the two human retinoblastoma cell lines SO-RB50 and HXO-RB44 with VEGF-targeted small interfering RNA (siRNA) expression plasmid significantly inhibited VEGF expression determined by real-time polymerase chain reaction (PCR), enzyme-linked immunosorbent assay and Western blot, whereas the control transfection showed no effects. The chemically synthesized VEGF siRNA dramatically suppressed tumor angiogenesis (CD34 immunohistochemistry) and tumor growth in the SO-RB50 subcutaneous xenograft model. Significant downregulation of VEGF expression both on messenger RNA and protein levels in VEGF-siRNA-treated SO-RB50 subcutaneous xenograft was confirmed by real-time PCR and Western blot compared to control. Our data demonstrate the suppression function on angiogenesis and tumor growth of retinoblastoma by VEGF-targeted RNAi. This novel therapeutic strategy promises to play a part in the clinical management of retinoblastoma.
血管内皮生长因子(VEGF)是肿瘤血管生成中最重要的血管生成生长因子之一,已证实其参与视网膜母细胞瘤的新生血管形成。在此,我们试图探讨靶向VEGF的RNA干扰(RNAi)是否能抑制视网膜母细胞瘤的血管生成和肿瘤生长。用靶向VEGF的小干扰RNA(siRNA)表达质粒稳定转染两个人视网膜母细胞瘤细胞系SO-RB50和HXO-RB44,通过实时聚合酶链反应(PCR)、酶联免疫吸附测定和蛋白质印迹法测定,显著抑制了VEGF表达,而对照转染则无此效果。化学合成的VEGF siRNA在SO-RB50皮下异种移植模型中显著抑制了肿瘤血管生成(CD34免疫组织化学)和肿瘤生长。与对照相比,通过实时PCR和蛋白质印迹法证实,VEGF-siRNA处理的SO-RB50皮下异种移植中VEGF表达在信使RNA和蛋白质水平上均显著下调。我们的数据证明了靶向VEGF的RNAi对视网膜母细胞瘤血管生成和肿瘤生长的抑制作用。这种新的治疗策略有望在视网膜母细胞瘤的临床管理中发挥作用。